Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas
Status:
Active, not recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a
recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory
gliomas containing the BRAFV600E or BRAF Ins T mutation.
Phase:
Early Phase 1
Details
Lead Sponsor:
Theodore Nicolaides MD University of California, San Francisco